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ABSTRACT Changes in serum glycans discriminate between disease statuses in can-
cer. A similar connection has not been established in the context of infectious
diseases such as tuberculosis (TB). The inﬂammation arising from infection by
Mycobacterium tuberculosis may affect host protein glycosylation,thereby provid-
ing information about disease status in TB. A mouse model of infection was used to
study glycoprotein N-glycosylation in serum. Following digestion of serum glycopro-
teins with peptide-N-glycosidase F (PNGase F), released glycans were permethylated
and analyzed by multidimensional mass spectrometry (MS). Conditions included na-
ive or Mycobacterium bovis BCG-vaccinated animals, which were either uninfected or
infected with M. tuberculosis. MS results were validated by lectin blotting. We found
that both glycoprotein fucosylation and sialylation were particularly sensitive to M.
tuberculosis infection. We observed that M. tuberculosis infection elevates serum IgM
levels and induces changes in glycosylation that could inform about the disease.
IMPORTANCE We demonstrate that M. tuberculosis infection inﬂuenced host protein
glycosylation in a mouse model. The mechanism by which infection modiﬁes gly-
cans in serum proteins is not understood. Investigation of the regulation of such
modiﬁcations by M. tuberculosis opens a new ﬁeld that could lead to the discovery
of novel biomarkers. Validation of such ﬁndings in human samples will reveal the
clinical relevance of these ﬁndings.
KEYWORDS IgM, Mycobacterium tuberculosis, fucosylation, glycans, immunoglobulin
M, mice
The glycome represents the entirety of carbohydrates present in molecules, cells,and tissues. A signiﬁcant body of data exists indicating that changes in the glycome
are linked to disease and, conversely, that infection and inﬂammation lead to changes
in the glycome (1). Considering that the host glycome is generated by a number of
enzymes, including glycosyltransferases, glycosidases, and nucleotide sugar transport-
ers acting at the level of the Golgi complex, any change in the metabolic status of the
cell can lead to changes in the sugar moieties added to proteins. Consequently,
infection by a pathogen and the associated inﬂammatory response may affect host
glycosylation. Interestingly, aberrantly glycosylated proteins are a hallmark of onco-
genic transformation, providing useful biomarkers for cancer progression (2). Moreover,
recent advances in glycoanalytical methods have facilitated high-throughput screens
for these serum biomarkers (3). Although serum glycome analysis seems to be a reliable
method to discriminate between cancer and control patients, there is little or no
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information supporting the notion that glycome changes correlate with states of
infection by a speciﬁc pathogen or with protection by vaccination. Recently, a corre-
lation between tuberculosis (TB) disease status in humans and glycosylation changes in
immunoglobulin Gs (IgGs) was demonstrated (4). IgGs isolated from individuals with
latent TB possessed enhanced Fc effector functions and drove macrophages to kill
intracellular Mycobacterium tuberculosis, indicating that differential glycosylation of
IgGs, not just differential expression of IgG subclass, can modulate the capacity to
control bacterial replication. In fact, this dimension of IgGs has already been extensively
studied in the context of other infectious agents, including inﬂuenza virus (5), HIV (6–8),
Ebola virus (9), and malaria agents (10).
The host response to M. tuberculosis plays a major role in the determination of the
different clinical manifestations of the disease. M. tuberculosis can persist within the
host for a lifetime, where it can reactivate due to various stimuli, including HIV infection,
diabetes, cancer, or malnutrition (11). In 2015, the WHO reported an estimated 9.4
million new cases of TB, with an estimated 1.5 million deaths (12). Despite the fact that
there are tools already in place to control the disease, TB is still the leading cause of
mortality and morbidity by a curable bacterial infection in the developing world. The
inﬂammation generated upon M. tuberculosis infection is necessary for the host de-
fense, yet can result in immunopathologic damage (13). It is assumed that a balanced
immune response that includes both pro- and anti-inﬂammatory responses is essential
for controlling bacterial proliferation within granulomas. Considering the magnitude
and diversity of the anti-TB immune response, we hypothesized that serum glycome
changes may occur and that these changes may inform about the disease status of the
host.
In this study, we study broad changes in serum glycoproteins beyond IgGs from
naive, infected, and Mycobacterium bovis BCG-vaccinated murine models of infection.
RESULTS
Protective efﬁcacy of BCG vaccination in murine model of M. tuberculosis
infection. We reproduced a typical BCG vaccination experiment where mice were
immunized with live BCG prior to an infection with the virulent strain of M. tuberculosis.
We observed a signiﬁcant 1 log of reduction in the number of lung CFU in vaccinated
versus unvaccinated mice 4 weeks after infection (Fig. 1A). This enhanced control of
bacterial replication in the lung correlated with decreased lung pathology, as shown by
reduced areas of inﬂammation measured as the percentage of diseased tissue (Fig. 1B
and C). We hypothesized that N-glycan changes must be occurring during M. tubercu-
losis infection and that the beneﬁcial effect of BCG vaccination must also impact the
FIG 1 Protective efﬁcacy of BCG immunization against M. tuberculosis infection. (A) CFU in the lungs of
individual C57BL/6 mice, immunized with 106 BCG bacteria 4 weeks after infection with a low dose of M.
tuberculosis H37Rv via aerosol (approximately 100 CFU). The results are pooled values from two similar
and independent experiments. (B) Representative H&E staining images from lungs of C57BL/6 mice sham
immunized (top) and BCG immunized (bottom) and aerosol infected with M. tuberculosis H37Rv for
4 weeks. (C) Morphometric analysis of lung histopathology by assessing the percentage of diseased
tissue. Experimental groups used 5 mice (**, P 0.01; ***, P 0.001).
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N-glycan structures of serum glycoproteins. To do this, we isolated serum from the
same animals in Fig. 1.
Alteration of the serum glycome uponM. tuberculosis infection.We investigated
glycoprotein N-glycosylation in serum of mice infected with M. tuberculosis by com-
paring the N-glycans released from serum proteins harvested from naive and BCG-
vaccinated mice with their M. tuberculosis-infected counterparts (Fig. 2 and data not
shown). Full mass spectrometry (MS) analysis (data not shown) detected the expression
of high-mannose-type, hybrid-type, complex-type biantennary, and complex-type tri-
antennary glycans (Fig. 2). The major N-glycans were disialylated, biantennary complex
glycans with or without core fucosylation (structures 11 and 17 in Fig. 2).
Comparing the serum glycomes of infected and naive mice, with and without BCG
vaccination, changes in glycosylation patterns were detected. The disialylated bianten-
nary complex glycan (structure 11 in Fig. 2A) was signiﬁcantly decreased in unvacci-
nated M. tuberculosis-infected mice relative to unvaccinated naive mice. Signiﬁcant
decreases were observed in di- and trisialylated triantennary complex glycans (struc-
tures 13 and 18 in Fig. 2A) in BCG-vaccinated and infected mice relative to vaccinated
FIG 2 Serum N-glycans from mouse models of M. tuberculosis infection. (A) Based on the intensities of N-glycan
signals for each structure, the prevalence of each N-glycan was quantiﬁed as a percentage of the total N-glycan
intensity in the indicated serum samples. The relative abundance calculated for each glycan is plotted as the
average from three independent measurements (biological replicates) with standard errors. Gray, red, green, and
blue bars indicate naive control, naive following M. tuberculosis infection, BCG control, and BCG following M.
tuberculosis infection, respectively. (B) To compare the relative abundance of each type of glycan across disease
status, the total relative abundance of each glycan type was summed separately for each group. (C) To compare
the relative abundance of core fucosylation across disease status, the total relative abundance of fucosylated and
nonfucosylated glycans was summed separately for both naive and BCG-vaccinated mice. Black bars and white bars
indicate nonfucosylated complex-type N-glycan and core fucosylated N-glycan, respectively. The averages
from three independent experiments with standard errors are shown. (*, P  0.05; **, P  0.01; both panel A
and panel B).
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and uninfected mice. Conversely, several core fucosylated complex glycans were
signiﬁcantly increased in M. tuberculosis-infected mouse serum (structures 14, 15, and
16 in Fig. 2A). When assessing differences in the relative abundance of glycan types, we
observed a signiﬁcant increase in complex and biantennary glycans in samples from
immunized and infected mice relative to mice only immunized (Fig. 2B). We observed
the opposite trend in triantennary and sialylated and hybrid-type glycans. No change
was generally observed between naive and M. tuberculosis-infected mice except for the
signiﬁcant reduction in M. tuberculosis-infected mice in the relative abundance of
sialylated complex-type glycans (Fig. 2B). The general theme of decreased nonfucosy-
lated complex and increased fucosylated complex glycans in M. tuberculosis-infected
mice was broadly consistent when comparing naive and BCG-immunized mice. To
assess the relevance of altered fucosylation for infection and vaccination responses, we
quantiﬁed the relative abundance of all N-glycans with or without core fucose (Fig. 2C).
In naive and BCG-vaccinated/uninfected mice, nonfucosylated glycans were present in
signiﬁcantly higher abundance than fucosylated glycans. However, infection with M.
tuberculosis in naive or vaccinated mice resulted in serum glycan proﬁles in which
fucosylated and nonfucosylated glycans were detected in similar abundance, consis-
tent with increased glycan core fucosylation in response to M. tuberculosis infection,
regardless of vaccination status.
To assess whether glycan proﬁles are predictive of disease or vaccination status, we
performed hierarchical clustering using the relative abundance of each of the 18
glycans we quantiﬁed across the four sample types. We calculated the fold change in
the abundance for each biological replicate of each sample type relative to the average
value of the abundance for each glycan in the naive sample (Fig. 3). Using this fold
change parameter, immunized mice exhibited glycomic proﬁles very similar to those of
naive mice. However, clustering of the fold changes in the glycomic proﬁle of M.
tuberculosis-infected mice again highlighted increased core fucosylation as a major
driver of the infection process, whether mice were immunized or not. The glycomic
proﬁles of all but one of the infected mice clustered separately from the immunized
and uninfected mice.
Identiﬁcation of serum glycoproteins with altered glycosylation upon M. tu-
berculosis infection. To identify glycoproteins with altered glycosylation, serum pro-
teins were separated by SDS-PAGE, blotted onto PVDF membranes, and probed with
lectins with well-deﬁned binding speciﬁcities. Aleuria aurantia lectin (AAL) binds to
N-glycans that are core fucosylated (Fig. 4A) (14, 15). AAL demonstrated a signiﬁcant
decrease in staining around 120 kDa in serum samples from M. tuberculosis-infected
and unvaccinated mice (Fig. 4A and B). Sambucus nigra agglutinin (SNA) lectin also
exhibited increased staining in this mass region of the blot, indicating enhanced
terminal 2-6-linked sialylation (Fig. 4C and D) (16). SNA binding was also increased in
the apparent mass range of 70 kDa in serum from M. tuberculosis-infected mice
independent of their vaccination status (Fig. 4C and D). A signiﬁcant increase in the
binding of AAL to the 70-kDa gel region was not detected (Fig. 4A and B). These results
suggest an association between M. tuberculosis infection and glycosylation changes in
subsets of serum proteins.
In-gel tryptic digestion and subsequent liquid chromatography-tandem MS analysis
(LC-MS/MS) indicated that the 70-kDa and the 120-kDa mass ranges are enriched in Ig
chain C region and the inter-alpha-trypsin inhibitor heavy chain (ITIH4), respectively
(Table 1). LC-MS/MS proteomic identiﬁcations were validated by immunoblotting using
speciﬁc antibodies to each protein (data not shown). Probing of immunoblots with
anti-Ig chain detected increased Ig chain in M. tuberculosis-infected serum sample
relative to serum from naive mice (data not shown), suggesting that the increase of
binding to SNA could be due to an increase in the protein levels of Ig chain.
Interestingly, no changes in Ig chain protein levels were observed in BCG samples,
indicating that the increase in SNA binding reﬂects increased moles of sialic acid per
mole of protein upon immunization. Validation of the ITIH4 protein assignment with
N-terminal speciﬁc antibody revealed differential processing in serum from BCG-
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immunized/uninfected control relative to BCG-immunized/infected mice (data not
shown). Considering that ITIH4 abundance changes have also been associated with
other infectious (17) and noninfectious conditions, such as hepatocellular carcinoma
(18) and ischemic stroke (19), the TB speciﬁcity of ITIH4 status was not investigated
further, and we chose to focus our analysis on the glycosylation status of serum IgM.
BCG vaccination impacts glycosylation of IgM. We puriﬁed IgM from serum in
order to characterize the speciﬁc glycosylation changes on IgM glycopeptides in
response to infection and immunization (Fig. 5A). Following in-gel tryptic digestion and
subsequent glycan release by peptide-N-glycosidase F (PNGase F) digestion, we quan-
tiﬁed the relative abundance of the 2 major N-glycans that we previously detected in
serum (structures 11 and 17, Fig. 2). We note, for comparison, that two glycans
dominate the characterized glycans found on human IgM; for both mouse and human
IgM, these glycans are sialylated, biantennary complex structures, although reported to
be undersialylated in human IgM (20). For each of the mouse IgM preparations we
analyzed, the core fucosylated form of the most abundant biantennary complex glycan
was more prevalent than the nonfucosylated form, regardless of infection or immuni-
zation status (Fig. 5B). Infection of naive mice increased the abundance of serum IgM
FIG 3 Hierarchical clustering of N-glycan relative abundances segregates mouse samples by disease
state. N-glycans harvested from naive (N), M. tuberculosis-infected (M), BCG-vaccinated uninfected (B), or
BCG-vaccinated and infected (MB) mice were quantiﬁed in three separate animals as biological replicates
(designated 1 to 3 for each mouse type). Relative glycan abundance was calculated for each glycan as
percentage of the total proﬁle, and the values for each biological replicate were compared to the average
of the abundance value for the naive mice (Navg). This ratio was deﬁned as the fold difference in relative
glycan abundance for each treatment condition relative to naive mice. The log2 of the ratio was taken
to facilitate comparison across samples and glycan abundance scales such that a value of 0 corresponds
to no change and each log increment corresponds to a 2-fold increase or decrease. Heat map clustering
of the fold differences indicates that the N-glycan proﬁle of BCG-vaccinated mice is similar to naive mice
(B/Navg); all of the B/Navg replicates cluster together. However, ﬁve of the six biological replicates of
infected mice, regardless of their vaccination status (M and MB replicates), exhibited glycan proﬁles
distinct from the naive (Navg) and vaccinated uninfected (B) proﬁle. The segregation of disease status
was driven most forcefully by increased abundance of core fucosylated glycans (glycans 6 to 8 and 14
to 16).
Serum N-Glycome Changes upon Mycobacterium Infection
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by 1.5-fold (data not shown), while core fucosylation was increased more than 5-fold
(Fig. 5C), indicating a signiﬁcant shift in the processing of IgM glycans as a result of M.
tuberculosis infection. However, BCG immunization blunted the increase in glycan
fucosylation in response to M. tuberculosis infection by more than 50% (5.5-fold versus
2.5-fold, Fig. 5C).
DISCUSSION
Most of the currently available tests to screen for TB are based on the detection of
bacterially derived molecules. Therefore, these tests are not able to assess disease
FIG 4 Detection of glycosylation differences by lectin blotting of serum proteins in infected mice. (A and C) Blotted mouse serum proteins
were probed with AAL (A) and SNA (C). Naïve and BCG denote serum harvested from mice without or with BCG vaccination, respectively.
Ctrl and Mtb denote serum harvested from mice without or with M. tuberculosis challenge, respectively. Lanes designated 1 to 12 indicate
replicate serum samples. Intensities of the bands at 70 kDa and 120 kDa were quantiﬁed using ImageJ (B and D). The asterisk indicates
P 0.05. The arrow and arrowhead indicate bands at 70 kDa and 120 kDa, respectively. M, molecular weight markers.
TABLE 1 Protein identiﬁcation in mouse serum samples by LC-MS/MS
Mass area (kDa)a Identiﬁed protein Scoreb Coverage (%) Mol wt (kDa) Accession no.c
120 Inter-alpha-trypsin inhibitor heavy chain H4 20.63 1.08 102.8 E9Q5L2
7 Immunoglobulin Mu chain 75.34 27.47 50.0 A0A075B5P6
Carboxylesterase 1C 45.71 20.58 61.0 P23953
Hemopexin 18.44 16.96 51.3 Q91X72
Histidine-rich glycoprotein 9.63 8.00 59.1 Q9ESB3
Tetratricopeptide repeat protein 29 8.34 3.18 54.3 E9QLU4
Vitronectin 7.20 5.44 54.8 P29788
aMolecular weight range for excised bands as indicated in Fig. 4.
bProbability score derived from Proteome Discoverer 1.4 analysis.
cUniProt accession number.
Kumagai et al.
March/April 2019 Volume 4 Issue 2 e00684-18 msphere.asm.org 6
 o
n
 Septem
ber 24, 2019 at UAM
/SERVICIO
 DE DO
CUM
ENTACIO
N
http://m
sphere.asm
.org/
D
ow
nloaded from
 
status based on host response (21). A largely unexplored area of investigation is
whether glycomic or glycoproteomic alterations can be detected in host serum as a
result of infection and whether these changes are informative regarding disease status
(22). Recent work on human serum samples from TB-infected patients showed that
immunoglobulin G, a major serum glycoprotein, is subject to differential glycosylation
depending on disease status (4). We undertook a broader investigation of serum
glycosylation, without bias for any particular protein, in mice infected with M. tuber-
culosis. We show that serum glycoproteins from animals infected with M. tuberculosis
were altered in abundance and in the nature of their glycosylation.
We observed that protein fucosylation and sialylation are particularly sensitive to M.
tuberculosis infection. We focused on ITIH4 and IgM proteins since lectin blotting and
LC-MS/MS proteomic analysis indicated that they were impacted by infection (Fig. 4).
Enhanced sialylation of the ITIH4 protein was detected in samples from M. tuberculosis-
infected mice relative to naive ones. However, variations in ITIH4 abundance have also
been associated with noninfectious inﬂammatory conditions such as hepatocellular
carcinoma (18) or ischemic stroke (19), as well as with other infectious responses (17),
suggesting that changes in the abundance or glycosylation of this serum protein are
not speciﬁc for TB infection. We investigated the glycosylation of IgM at higher
resolution by immunoafﬁnity purifying it from serum and then separating it from other
FIG 5 N-glycan composition of serum IgM. The IgM component was enriched and puriﬁed by immu-
noafﬁnity precipitation and SDS-PAGE from the indicated serum samples. Glycans were released by
PNGase F digestion from the excised gel bands and analyzed by total ion monitoring (TIM) following
permethylation. (A) TIM scans were ﬁltered for loss of a NeuGc residue (Δm/z 203.5, doubly
charged) to reveal the presence of the major sialylated biantennary glycans. The integrated signals
associated with MS/MS fragments for the indicated glycan structures are shown as traces across scan
time. (B) Signal intensities detected for the neutral loss fragment ions at m/z 1,235.1 (doubly
charged NeuGc1Gal2GlcNAc2Man3GlcNAc2) and at m/z 1,332.1 (doubly charged NeuGc1Gal2GlcNAc2
Man3GlcNAc2Fuc1) are shown for the indicated serum samples. (C) The ratio of the signal intensities for
the fucosylated biantennary disialylated glycan was normalized to its nonfucosylated form for each of the
serum samples to quantify the relative abundance changes. Black, red, green, and blue traces and bars
indicate naive control, naive following M. tuberculosis infection, BCG control, and BCG following M.
tuberculosis infection, respectively.
Serum N-Glycome Changes upon Mycobacterium Infection
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contaminants by SDS-PAGE (Fig. 5). The glycans released from in-gel-digested IgM
peptides were representative of the whole-serum glycan proﬁle in that the two major
glycans of IgM were also detected as the two major glycans of serum (structures 11 and
17 in Fig. 2). However, compared to the glycans of whole serum, the relative abundance
of these two dominant glycans was reversed on IgM. The core-fucosylated glycan
(structure 17) was detected at between 2- and 5.5-fold higher abundance than the
nonfucosylated glycan (structure 11), depending on disease status. Furthermore, im-
munization with BCG modulates the magnitude of the change in fucosylation resulting
from infection. Since antibody glycosylation can be greatly affected by immunization,
inﬂammation, and disease progression (23), we cannot separate changes in glycosyla-
tion resulting from BCG vaccination from those resulting from differences in inﬂam-
mation in vaccinated mice. Furthermore, it is possible that an analysis focused on the
glycosylation of antibodies speciﬁc to mycobacterial antigens would reveal new and
different patterns from those apparent from total immunoglobulin preparations. Nev-
ertheless, we have observed that the glycosylation status of an individual serum protein
may trend differently than would be predicted by the glycan proﬁle of whole serum;
combinations of seemingly contradictory elements (decreased fucosylated serum gly-
cans but increased IgM protein fucosylation) may provide informative features for
assessing disease status. In addition, we observed that one mouse from the group of
BCG-vaccinated and M. tuberculosis-infected mice clustered with the vaccinated, unin-
fected group (Fig. 3). Tracing the identity of this mouse, we detected that it carried
a higher number of CFU, suggesting that the context of glycosylation can also be
microbe related.
The key result in this study was the demonstration that M. tuberculosis infection
inﬂuenced host protein glycosylation in mice. The mechanism by which infection or
vaccination modulates the structural characteristics of the glycome in a protein-speciﬁc
manner is not currently understood. Altered Golgi trafﬁcking, substrate availability, or
enzyme targeting within the secretory apparatus is a possible point of regulation that
could be affected by infection. Additionally, glycoprotein modiﬁcations could be edited
or inﬂuenced by secreted hydrolases or glycosyltransferases in the serum (24, 25).
Investigation of the regulation of such modiﬁcations by M. tuberculosis opens a new
ﬁeld that could lead to the discovery of novel biomarkers for the disease. To that end,
the data presented here provide a baseline appreciation of the glycomic and glyco-
proteomic complexity associated with M. tuberculosis infection and disease status that
can be expanded to include other glycoprotein targets and other species-speciﬁc
features, including those that may be key for assessing human disease status. Deter-
mining the diagnostic and prognostic utility of quantitative and qualitative aspects IgM
glycosylation in human M. tuberculosis infection will require correlation of these pa-
rameters with diseased states in clinical settings. Validation of such studies in a set of
human serum samples, reﬂecting a range of different clinical scenarios, is under way.
The outcome of such experiments will inform about the connection between mouse
and human serology and the clinical relevance of these results.
MATERIALS AND METHODS
Strains. M. bovis BCG Pasteur and M. tuberculosis H37Rv were grown in Middlebrook 7H9 supple-
mented with 10% (vol/vol) OADC enrichment (Becton, Dickinson Microbiology Systems, Sparks, MD),
0.5% (vol/vol) glycerol, with or without 0.05% (vol/vol) Tyloxapol for 14 days in a 5% CO2 incubator at
37°C.
Immunization. C57BL/6 female mice between 6 and 8 weeks old were purchased from Jackson
Laboratories (Bar Harbor, ME). All procedures involving mice were reviewed and approved by the Animal
Use and Care Committee of the Albert Einstein College of Medicine. Animals were maintained in a
speciﬁc-pathogen-free animal facility under animal biosafety level 2 conditions for all experiments except
for those involving infection with virulent M. tuberculosis, for which animal biosafety level 3 conditions
were used. Animals were immunized subcutaneously with 1 million BCG bacteria 6 weeks prior to an
infection with virulent M. tuberculosis. BCG was prepared for immunization as previously described (26).
Mouse infection. Aerogenic challenge was done using a whole-body exposure aerosol chamber
(Mechanical Engineering Workshop) custom ﬁtted to a class III biosafety cabinet (Baker) to deliver
approximately 100 CFU per animal of M. tuberculosis (H37Rv). Immunized mice were infected 3 weeks
after immunization. Mice were euthanized 30 days after challenge. Lungs of individual mice were
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aseptically removed and homogenized separately in 5 ml normal saline plus 0.05% Tyloxapol using a
Seward Stomacher 80 blender (Tekmar). The homogenates were diluted serially and plated on Middle-
brook 7H11 agar to determine CFU of M. tuberculosis. Dilutions of 102 and 103 and of 102 and 101
were plated when counting CFU in lungs and spleens, respectively. Animals infected with M. tuberculosis
H37Rv were observed at least twice daily until they died or became moribund and were euthanized.
Serum collection. Blood was collected by cardiac puncture and centrifuged at 5,000 g, and serum
was stored at 80°C.
Histology. Lungs were removed and ﬁxed in 10% neutral buffered formalin (Fisher Scientiﬁc, Fair
Lawn, NJ). Tissues were embedded with parafﬁn, sectioned at 5-m thickness, and stained with
hematoxylin and eosin. Five different lung sections per mouse were analyzed. Slides were scanned with
a Perkin-Elmer P250 high-capacity slide scanner (Waltham, MA) at 2,000 dots per inch (dpi). Digitized
images were then analyzed using ImageJ software to calculate the total disease area occupied by
granuloma and the percentage of lung surface affected by pneumonia as well as the number of inﬁltrates
per lung. The total disease area for the entire lung section was measured by adding the values for each
lesion. The total percentage of diseased tissue was calculated by dividing the total disease area by the
entire lung section and multiplying by 100, using ImageJ software.
SDS-PAGE and lectin immunoblotting. The protein in 3 l of mouse serum was precipitated with
ice-cold 75% acetone, and the pellet was solubilized in 100 l of Laemmli sample buffer. Five microliters
of solubilized sample (equivalent to 0.15 l of serum) was separated on a 4 to 15% TGX gradient gel
(Bio-Rad), transferred to a polyvinylidene diﬂuoride (PVDF) membrane, and then probed with biotinyl-
ated lectins (Sambucus nigra [SNA], Phaseolus vulgaris erythroagglutinin [E-PHA], Phaseolus vulgaris
agglutinin [L-PHA], and Aleuria aurantia [AAL] lectins [Vector Laboratories, Burlingame, CA]) after
blocking with 3% BSA in TBS. Probed membranes were incubated with Vectastain ABC-AP (Vector
Laboratories), and bound lectin was detected with BCIP/NBT (Kirkegaard & Perry Laboratories, Inc.,
Gaithersburg, MD). Alternatively, PVDF membranes were incubated with anti-inter-alpha-trypsin inhibitor
heavy chain H4 (ITIH4) antibody (ab180139; Abcam, Cambridge, MA), anti-mouse IgM conjugated to
horseradish peroxidase (HRP) (A8786; Sigma), anti-ITIH4 antibody (sc-515353; Santa Cruz), goat anti-
rabbit IgG conjugated to AP (Promega, Madison, WI), and rabbit anti-mouse IgG conjugated to AP
(Promega, Madison, WI). Incubation with secondary antibodies was followed by detection with SigmaFast
DAB with metal enhancer (Sigma, Saint Louis, MO) or incubation with the BCIP/NBT phosphatase
substrate as appropriate.
In-gel trypsin digestion and protein identiﬁcation. Identiﬁcation of proteins of interest was
performed as previously described (27, 28). Liquid chromatography-tandem mass spectrometry was
performed with an LTQ-Orbitrap Discovery mass spectrometer (Thermo Fisher Scientiﬁc) equipped with
a nanospray ionization source. The resulting data were searched against the mouse proteome database
by using the Sequest algorithm (Proteome Discoverer 1.4; Thermo Scientiﬁc). Sequest parameters were
set to allow 35.0 ppm of precursor ion mass tolerance and 0.8 Da of fragment ion tolerance with
monoisotopic masses. Tryptic peptides were allowed with up to 2 missed internal cleavage sites, and
differential modiﬁcations were allowed for carboxyamidomethylation of cysteine and oxidation of
methionine. The resulting peptide data were ﬁltered by charge versus cross-correlation (Xcorr) to result
in a stringent false discovery rate of 1%.
N-glycan analysis. N-glycans released from serum glycoproteins by digestion with PNGase F
(Prozyme, Hayward, CA) were permethylated prior to analysis by nanospray ionization multidimensional
mass spectrometry (NSI-MSn) as previously described (29). Glycans released from equivalent amounts of
protein were analyzed for comparison across treatments. Graphical representations of monosaccharide
residues are presented in accordance with the broadly accepted Symbolic Nomenclature for Glycans
(SNFG) (30), and glycan analysis was performed in accordance with the MIRAGE guidelines for glycomic
studies (31).
IgM immunoprecipitation and glycan analysis. Aliquots of serum (50-l total volume) were pooled
from each sample type and diluted to 500 l with TBS supplemented with 0.1% Triton X-100 and
complete protease inhibitor mix (Roche). A suspension (300 l) of anti-mouse Ig chain antibody
immobilized on agarose beads (A4540; Sigma) was added, and the mixture was incubated for 1 h at 4°C
with agitation. Beads were subjected to sequential washes with 1.5 ml of PBS, and the bound IgMs were
eluted with 1.5 ml of an 0.5 M acetic acid solution supplemented with 150 mM NaCl. After elution, salts
were removed in a 10-kDa-cutoff spin column, and the resulting IgM preparations were resolved on a 4
to 15% SDS-PAGE gel and stained with Coomassie brilliant blue (CBB) G250. The IgM heavy chain band
at approximately 70 kDa was excised and stored at 4°C until use. The gel band was minced into 1-mm
cubes subjected to in-gel trypsin digestion. N-glycans were released from the resulting peptides by
PNGase F digestion, permethylated, and analyzed by NSI-MSn as described above. In addition to full MS
analysis, permethylated glycans were also analyzed using the TIM (total ion monitoring) functionality of
the Xcalibur instrument control and data acquisition software (Thermo Fisher). TIM analysis captures
MS/MS data in discrete m/z windows across a user-deﬁned mass range, providing validation of structural
assignments associated with glycan peaks detected in full MS spectra. For each sample, TIM analysis
generates 1,500 to 2,000 individual MS/MS spectra, which can be ﬁltered for the presence of informative
fragment ions. Filtered spectra were subjected to manual inspection and fragment ion annotation in
order to validate the detected structural features.
Statistics. Standard one-way ANOVA followed by Tukey’s multiple-comparison test of the means was
used to determine statistical signiﬁcance of immune responses and protective efﬁcacies of BCG vacci-
nation and intensity of immunoblot bands. P 0.05 was considered statistically signiﬁcant. Error bars
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represent SEM. Hierarchical clustering of glycan structural features was achieved as previously described
(32).
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